Ubs Asset Management Americas Inc Travere Therapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $345 Billion
- Q2 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 178,749 shares of TVTX stock, worth $2.5 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
178,749
Previous 103,980
71.91%
Holding current value
$2.5 Million
Previous $801,000
83.4%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding TVTX
# of Institutions
184Shares Held
89.8MCall Options Held
137KPut Options Held
181K-
Black Rock Inc. New York, NY7.64MShares$107 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.5MShares$105 Million0.8% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.37MShares$103 Million1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.62MShares$92.6 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.48MShares$62.7 Million1.14% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $898M
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...